                         SEQUENCE LISTING

<110>  Life Sciences Research Partners vzw
 
<120>  Minimally toxic prodrugs

<130>  LSRP-061 PCT

<150>  US 61/746,621
<151>  2012-12-28

<160>  10    

<170>  PatentIn version 3.5

<210>  1
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic oligopeptide

<400>  1

Ala Leu Gly Pro 
1               


<210>  2
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic oligopeptide

<400>  2

Ala Leu Ala Leu 
1               


<210>  3
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic oligopeptide

<400>  3

Ala Leu Ala Pro 
1               


<210>  4
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic oligopeptide

<400>  4

Thr Ser Gly Pro 
1               


<210>  5
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic oligopeptide

<400>  5

Thr Ser Ala Pro 
1               


<210>  6
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic oligopeptide

<400>  6

Lys Leu Gly Pro 
1               


<210>  7
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic oligopeptide

<400>  7

Lys Leu Ala Pro 
1               


<210>  8
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic oligopeptide

<400>  8

Ala Leu Lys Pro 
1               


<210>  9
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic oligopeptide

<400>  9

Thr Ser Lys Pro 
1               


<210>  10
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  synthetic oligopeptide

<400>  10

Lys Leu Lys Pro 
1               


